**TBAbs [........] (RR, < 40%)**

- Reduced thyroid uptake, 1% (RR, 3–8%)

**TSAbs [———] (RR, < 180%)**

- Increased thyroid uptake, 12% (RR, 3–8%)

**Time (weeks) from starting IFN therapy**

- 0: TSH: 1.98, fT4: 21.5, fT3: 4.9, TSAb: 192.2%, TBAb: 124.8%
- 4: TSH: 0.21, fT4: 22.5, fT3: 5.1
- 8: TSH: 0.18, fT4: 20.7, fT3: 5.3
- 12: TSH: < 0.03, fT4: 28.9, fT3: 6.9, TSAb: 345.2%, TBAb: 24.9%
- 16: TSH: < 0.03, fT4: 28.9, fT3: 6.9, TSAb: 345.2%, TBAb: 24.9%
- 20: TSH: < 0.03, fT4: 28.9, fT3: 6.9, TSAb: 345.2%, TBAb: 24.9%
- 24: TSH: < 0.03, fT4: 28.9, fT3: 6.9, TSAb: 345.2%, TBAb: 24.9%

**Thyroxine Dosing**

- Thyroxine 150 ug
- Thyroxine 100 ug
- Thyroxine 50 ug
- No thyroxine

**Thyroid Uptake**

- Reduced thyroid uptake, 1% (RR, 3–8%)
- Increased thyroid uptake, 12% (RR, 3–8%)